Figure 3.

PRRT with [¹⁷⁷Lu]Lu-DOTA-TATE in MPC and MTT allograft mice treated with epigenetic drugs; (A) Sequence of investigations after ET with VPA (250 mg/kg) and DAC (1 mg/kg) as combination doses followed by PRRT with [¹⁷⁷Lu]Lu-DOTA-TATE (70 MBq/animal, equivalent to 1.2 nmol), (B) Maximum intensity projections of SPECT images; (A_{V 24 h}) activity concentration 24 hours after radiotracer injection; (dotted regions) uptake in tumors; (C) Effects of ET on activity concentrations in tumors; (dashed horizontal lines) A_V responder thresholds compared to [PRRT] cohorts; (D) Changes in tumor volume in response to treatments; (log₂ fold changes) number of volume doublings compared to treatment start; (dotted vertical lines) time points of ET; (dashed vertical lines) initiation of PRRT; (dashed red connecting curve) extended follow-up in a sub-cohort of MTT allograft mice with highest activity concentrations in tumors (n = 3); (E) Maximum changes in tumor volume during six days of PRRT; (F) Correlation between the initial activity concentrations in tumors and tumor re-growth; (GAT) growth arrest of tumors; see Supplemental Information 2.3 for additional data.